Evidence map›Paper›PMID 36373759›Full record

Observational studyClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Assessment of Healthcare Resource Utilization by Anticoagulant Heparinoid Dosage Level in Patients Hospitalized with COVID-19.

Keith Robinson, Laura L Schott, Tom Matthews, Manu Tyagi, Vivek B Ajmani, Nancy Sacco, Zhun Cao

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Keith RobinsonMedical and Scientific Management, Syneos Health, Morrisville, NC, USA.
Laura L SchottPINC AI™ Applied Sciences®, 43690Premier Inc., Charlotte, NC, USA.ORCID 0000-0001-8386-395X
Tom MatthewsSpecialty Pharma, Meitheal Pharmaceuticals, Inc., Chicago, IL, USA.
Manu TyagiPINC AI™ Applied Sciences®, 43690Premier Inc., Charlotte, NC, USA.
Vivek B AjmaniPINC AI™ Applied Sciences®, 43690Premier Inc., Charlotte, NC, USA.
Nancy SaccoSpecialty Pharma, Meitheal Pharmaceuticals, Inc., Chicago, IL, USA.
Zhun CaoPINC AI™ Applied Sciences®, 43690Premier Inc., Charlotte, NC, USA.
Premier Research Group · USSyneos Health (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim was to describe inpatients with COVID-19 empirically prescribed heparinoid anticoagulants and compare resource utilization between prophylactic/low-dose and therapeutic/high-dose groups.

Indexed as

COVID-19 Drug TreatmentHeparinoidsAnticoagulantsHospitalizationHumansIntensive Care UnitsPatient Acceptance of Health CareRetrospective StudiesAnticoagulantsHeparinoidsanticoagulantsCOVID-19healthcare resource utilizationheparinsprophylaxisthrombosis

Identifiers

PMID36373759
PMCPMC9663615
OpenAlexW4309164937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.